Press release
Currently, 10+ Key Companies are Working to Develop 10+ Pipeline Therapies for the Lymphoedema Treatment
Lymphoedema Treatment
In the report, a detailed description of the drug is proffered, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers in-depth commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed phase. Additionally, it presents the ongoing developments in the therapeutics segment including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Lymphoedema Pipeline Analysis
The report provides insights into:
The report provides detailed insights about companies that are developing therapies in the Lymphoedema Market.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lymphoedema treatment.
Lymphoedema key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Lymphoedema Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Lymphoedema market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for Sample PDF: https://www.delveinsight.com/report-store/lymphoedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Lymphoedema Therapeutics Analysis
There are approx. 10+ key companies which are developing therapies for Lymphoedema. The companies which have their Lymphoedema drug candidates in the most advanced stage, i.e. phase II include, Herantis Pharma.
Some of the key companies in the Lymphoedema Therapeutics Market include:
Herantis Pharma
PureTech health
AnGes
Adepthera
And others
Lymphoedema Emerging Drugs
Currently, more than 10+ Pipeline therapies are under development for the treatment of Lymphoedema. The therapies are in different stages of clinical development, expected to hit the market in the coming years.
Lymfactin: Herantis Pharma
Lymfactin is currently in Phase 2 trial clinical study. It is being developed by Herantis Pharma. It is a gene therapy product, which delivers the human gene coding for VEGF-C and thereby promotes the formation of new lymphatic vessels.
Learn more about the emerging therapies in the Lymphoedema Therapeutics Market, at:
https://www.delveinsight.com/sample-request/lymphoedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Lymphoedema Current Treatment Patterns
4. Lymphoedema - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Lymphoedema Late Stage Products (Phase-III)
7. Lymphoedema Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Lymphoedema Discontinued Products
13. Lymphoedema Product Profiles
14. Lymphoedema Key Companies
15. Lymphoedema Key Products
16. Dormant and Discontinued Products
17. Lymphoedema Unmet Needs
18. Lymphoedema Future Perspectives
19. Lymphoedema Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Request for the Sample PDF (to get a detailed understanding of the TOC, Tables, and Figures included in the report), at: https://www.delveinsight.com/report-store/lymphoedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/lymphoedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Currently, 10+ Key Companies are Working to Develop 10+ Pipeline Therapies for the Lymphoedema Treatment here
News-ID: 2681367 • Views: …
More Releases from DelveInsight Business Research
Immune Checkpoint Inhibitors Market Outlook 2034: Competitive Landscape, Pipelin …
DelveInsight's latest report, "Immune Checkpoint Inhibitors Market Forecast (2020-2034)", provides an in-depth analysis of one of the most transformative areas in oncology. According to DelveInsight estimates, the Immune Checkpoint Inhibitors (ICI) market is expected to grow at a decent CAGR throughout the forecast period, driven by the rising global burden of cancer, advances in immuno-oncology, increasing healthcare expenditures, and the anticipated approval of novel ICIs across the 7MM [the United…
HPK1 Inhibitors Market Outlook 2034: Competitive Landscape, Pipeline Advancement …
(Albany, USA, September 2025) - DelveInsight has released its latest report, "HPK1 Inhibitor Competitive Landscape And Market Forecast - 2034," delivering an in-depth analysis of the rapidly evolving HPK1 inhibitor market. The report offers a comprehensive overview of the epidemiology, drug uptake, treatment landscape, competitive intelligence, and market dynamics shaping the outlook of HPK1 inhibitors across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To know…
Focal Adhesion Kinase (FAK) Inhibitors Market Outlook 2034: Scientific Advances, …
(Albany, USA, September 2025) - Focal Adhesion Kinase (FAK), also known as PTK2, has emerged as one of the most promising molecular targets in oncology research and therapy development. Encoded by the PTK2 gene, FAK is a non-receptor tyrosine kinase critically involved in signal transduction mediated by growth factor receptors and integrins. Increasing evidence shows that overexpression of FAK is directly associated with tumor progression, therapy resistance, and poor clinical…
Thyroid Eye Disease Market Set for Robust Expansion Through 2034, DelveInsight R …
DelveInsight's "Thyroid Eye Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Thyroid Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Thyroid Eye Disease…
More Releases for Lymphoedema
Lymphoedema Market expected to reach $6.2 billion by 2034
Lymphoedema is a chronic, progressive condition characterized by the abnormal accumulation of lymphatic fluid, leading to swelling, discomfort, and reduced mobility. It often develops as a result of lymphatic system damage or obstruction, typically following cancer treatment (such as surgery or radiation) or due to congenital abnormalities. Left unmanaged, lymphoedema can cause recurrent infections, tissue changes, and significant reductions in quality of life.
Download Full PDF Sample Copy of Market Report…
Global Lymphoedema Market Report Forecast to 2021-2027 |key players are 3A Healt …
The aim of the report is to provide consumers with detailed information on the Lymphoedema Market. The Primary lymphedema and secondary lymphedema are the two kinds of lymphedema. The increased frequency of lymphedema linked with cancer, as well as improved knowledge of illness early detection, may account for the significant share of the section in this report . The Lymphoedema Market is divided into hospitals, diagnostic centres, research & academic…
Lymphoedema Market Survey Report 2021 Along with Statistics, Forecasts till 2026
The Lymphoedema market report provides an overview of Lymphoedema, Lymphoedema applications, and its PEST Analysis. Additionally, the report provides insight on the Lymphoedema market share of the individual Lymphoedema, current and forecasted Lymphoedema market size from 2018 to 2026 segmented by seven major markets. The report also covers the market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of…
Global Lymphoedema Diagnostics Market 2021 - Industry Insights, Drivers, Top Tre …
Lymphoedema Diagnostics
The report titled “Lymphoedema Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, And Forecast, 2020-2026” utilizing diverse methodologies aims to examine and put forth in-depth and accurate data regarding the global Lymphoedema Diagnostics Market. The report is segregated into different well-defined sections to provide the reader with an easy and understandable informational document. Further, each section is elaborated with all the required data to gain knowledge about the…
Dee Stringer, Lymphoedema Therapist: "Every Therapist Should Use DEEP OSCILLATIO …
"I have worked in Lymphoedema care for five years and have purchased pumps & lasers as well as applying techniques such as MLD and FG-MLD. I have had recognised awards in the care industry using all of these.
Nottingham, Nottinghamshire, UK, March 31, 2016 -- "I have worked in Lymphoedema care for five years and have purchased pumps & lasers as well as applying techniques such as MLD and FG-MLD. I…
Attention: Lymphoedema Health Care Professionals - New Research Study Being Unde …
Attention: Lymphoedema Health Care Professionals - Please Help Melanie Thomas By Completing Questionnaire on Reducing the Risk of Breast Cancer Related Lymphoedema.
Nottingham, Nottinghamshire, UK, March 17, 2016 -- Calling All Lymphoedema Health Care Professionals: Nurses, Doctors, Physiotherapists, Occupational Therapists, MLD DLT Therapists and unregistered support staff (if they see breast cancer patients)
Melanie Thomas, National Clinical Lead for Lymphoedema Services in Wales and Lymphoedema Physiotherapist requires help. As part of her…
